Tumor‐dendritic cell fusion as a basis for cancer immunotherapy
| Autor: | Jorgen Kjaergaard, Suyu Shu, Hide Kuriyama, Keiji Shimizu, Walter T. Lee, Hiro Tanaka |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Lung Neoplasms
CD30 medicine.medical_treatment Mice Inbred Strains Hybrid Cells Cell Fusion Mice 03 medical and health sciences 0302 clinical medicine Cancer immunotherapy Antigen Animals Medicine Tumor marker Mice Inbred BALB C Cell fusion business.industry Vaccination Dendritic Cells Immunotherapy Dendritic cell Flow Cytometry beta-Galactosidase Electric Stimulation Tumor antigen Lac Operon Otorhinolaryngology 030220 oncology & carcinogenesis Immunology Neoplastic Stem Cells 030211 gastroenterology & hepatology Surgery business Spleen |
| Zdroj: | Otolaryngology–Head and Neck Surgery. 132:755-764 |
| ISSN: | 1097-6817 0194-5998 |
| DOI: | 10.1016/j.otohns.2005.01.018 |
| Popis: | Objective To establish the basis for use of allogeneic dendritic-tumor fusion cells. Study design Fusion cells were created by electrofusion. We used 2 allogeneic murine tumor lines (D5 and 4T1) that were virally transduced to express the antigen (β-galactosidase) as a surrogate tumor marker. Results Cross-immunization was achieved with irradiated allogenic tumor cells. Successful electrofusion of dendritic cells and tumor cells was confirmed by using fluorescence-activated cell sorting and cytospin. Significant responses were shown in immunized mice against tumor challenge and established 3-day pulmonary metastasis with fusion cells. Conclusions Allogeneic tumor sharing a common tumor antigen can immunize against syngeneic tumor challenge. Fusion cells showed successful immunization against tumor challenge and showed regression of 3-day established pulmonary metastasis. Significance These preclinical studies provide evidence that an allogenic tumor-dendritic cell fusion vaccine is a valid approach for head and neck cancer immunotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text